Your browser doesn't support javascript.
loading
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
Schwedt, Todd J; Lipton, Richard B; Ailani, Jessica; Silberstein, Stephen D; Tassorelli, Cristina; Guo, Hua; Lu, Kaifeng; Dabruzzo, Brett; Miceli, Rosa; Severt, Lawrence; Finnegan, Michelle; Trugman, Joel M.
Afiliación
  • Schwedt TJ; Department of Neurology, Mayo Clinic, Phoenix, AZ, USA.
  • Lipton RB; Albert Einstein College of Medicine, Bronx, NY, USA.
  • Ailani J; MedStar Georgetown University Hospital, Washington, DC, USA.
  • Silberstein SD; Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
  • Tassorelli C; IRCCS Mondino Foundation, Headache Science Center, Pavia, Italy.
  • Guo H; Department of Neurology, University of Pavia, Pavia, Italy.
  • Lu K; Neuroscience Development, AbbVie, Madison, NJ, USA.
  • Dabruzzo B; Neuroscience Development, AbbVie, Madison, NJ, USA.
  • Miceli R; Neuroscience Development, AbbVie, Madison, NJ, USA.
  • Severt L; Neuroscience Development, AbbVie, Madison, NJ, USA.
  • Finnegan M; Neuroscience Development, AbbVie, Madison, NJ, USA.
  • Trugman JM; Neuroscience Development, AbbVie, Madison, NJ, USA.
Cephalalgia ; 42(1): 3-11, 2022 01.
Article en En | MEDLINE | ID: mdl-34521260
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trastornos Migrañosos Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Cephalalgia Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trastornos Migrañosos Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Cephalalgia Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos